COMPLETE TEST BANK FOR
PHARMACOLOGY A PATIENT-CENTERED NURSING
PROCESS APPROACH, 11TH EDITION
BY LINDA E. MCCUISTION | VERIFIED CHAPTER'S 1 - 58 |
COMPLETE ANSWERS
,TABLE OF CONTENTS
CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE ........................................................ 4
CHAPTER 02: DRUG DEVELOPMENT AND ETHICAL CONSIDERATIONS ...................................................... 11
CHAPTER 03: PHARMACOKINETICS AND PHARMACODYNAMICS .............................................................. 21
CHAPTER 04: PHARMACOGENETICS ........................................................................................................... 39
CHAPTER 05: COMPLEMENTARY AND ALTERNATIVE THERAPIES............................................................... 44
CHAPTER 06: PEDIATRIC CONSIDERATIONS................................................................................................ 50
CHAPTER 07: GERIATRIC CONSIDERATIONS ............................................................................................... 59
CHAPTER 08: DRUGS IN SUBSTANCE USE DISORDER.................................................................................. 66
CHAPTER 09: SAFETY AND QUALITY ........................................................................................................... 74
CHAPTER 10: DRUG ADMINISTRATION ....................................................................................................... 82
CHAPTER 11: DRUG CALCULATIONS ........................................................................................................... 88
CHAPTER 12: FLUID VOLUME AND ELECTROLYTES ..................................................................................... 94
CHAPTER 13: VITAMIN AND MINERAL REPLACEMENT ............................................................................. 106
CHAPTER 14: NUTRITIONAL SUPPORT ...................................................................................................... 115
CHAPTER 15: ADRENERGIC AGONISTS AND ANTAGONISTS ..................................................................... 125
CHAPTER 16: CHOLINERGIC AGONISTS AND ANTAGONISTS .................................................................... 132
CHAPTER 17: STIMULANTS ....................................................................................................................... 141
CHAPTER 18: DEPRESSANTS...................................................................................................................... 146
CHAPTER 19: ANTISEIZURE DRUGS ........................................................................................................... 155
CHAPTER 20: DRUGS FOR PARKINSONISM AND ALZHEIMER DISEASE ..................................................... 164
CHAPTER 21: DRUGS FOR NEUROMUSCULAR DISORDERS AND MUSCLE SPASMS .................................. 172
CHAPTER 22: ANTIPSYCHOTICS AND ANXIOLYTICS .................................................................................. 180
CHAPTER 23: ANTIDEPRESSANTS AND MOOD STABILIZERS ..................................................................... 189
CHAPTER 24: ANTIINFLAMMATORIES....................................................................................................... 198
CHAPTER 25: ANALGESICS ........................................................................................................................ 207
CHAPTER 26: PENICILLINS, OTHER BETA-LACTAMS, AND CEPHALOSPORINS .......................................... 216
CHAPTER 27: MACROLIDES, OXAZOLIDINONES, LINCOSAMIDES, GLYCOPEPTIDES, KETOLIDES, AND
LIPOPEPTIDES ............................................................................................................................................ 223
CHAPTER 28: TETRACYCLINES, GLYCYLCYCLINES, AMINOGLYCOSIDES, AND FLUOROQUINOLONES ...... 228
CHAPTER 29: SULFONAMIDES AND NITROIMIDAZOLES ANTIBIOTICS ..................................................... 233
,CHAPTER 30: ANTITUBERCULARS, ANTIFUNGALS, AND ANTIVIRALS ....................................................... 239
CHAPTER 31: ANTIMALARIALS, ANTHELMINTICS, AND PEPTIDES ............................................................ 250
CHAPTER 32: HIV- AND AIDS-RELATED DRUGS ......................................................................................... 254
CHAPTER 33: TRANSPLANT DRUGS ........................................................................................................... 259
CHAPTER 34: VACCINES ............................................................................................................................ 262
CHAPTER 35: ANTICANCER DRUGS ........................................................................................................... 268
CHAPTER 36: TARGETED THERAPIES TO TREAT CANCER .......................................................................... 274
CHAPTER 37: BIOLOGIC RESPONSE MODIFIERS ........................................................................................ 279
CHAPTER 38: UPPER RESPIRATORY DISORDERS ....................................................................................... 286
CHAPTER 39: LOWER RESPIRATORY DISORDERS ...................................................................................... 293
CHAPTER 40: CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS ................................... 301
CHAPTER 41: DIURETICS ........................................................................................................................... 314
CHAPTER 42: ANTIHYPERTENSIVES ........................................................................................................... 320
CHAPTER 43: ANTICOAGULANTS, ANTIPLATELETS, AND THROMBOLYTICS ............................................. 329
CHAPTER 44: ANTIHYPERLIPIDEMICS AND DRUGS TO IMPROVE PERIPHERAL BLOOD FLOW ................. 340
CHAPTER 45: GASTROINTESTINAL TRACT DISORDERS.............................................................................. 348
CHAPTER 46: ANTIULCER DRUGS .............................................................................................................. 358
CHAPTER 47: EYE AND EAR DISORDERS .................................................................................................... 367
CHAPTER 48: DERMATOLOGIC DISORDERS .............................................................................................. 373
CHAPTER 49: PITUITARY, THYROID, PARATHYROID, AND ADRENAL DISORDERS ..................................... 380
CHAPTER 50: ANTIDIABETICS .................................................................................................................... 392
CHAPTER 51: URINARY DISORDERS .......................................................................................................... 403
CHAPTER 52: PREGNANCY AND PRETERM LABOR .................................................................................... 410
CHAPTER 53: LABOR, DELIVERY, AND POSTPARTUM ............................................................................... 421
CHAPTER 54: NEONATAL AND NEWBORN ................................................................................................ 428
CHAPTER 55: WOMEN’S REPRODUCTIVE HEALTH .................................................................................... 431
CHAPTER 56: MEN’S HEALTH AND REPRODUCTIVE DISORDERS .............................................................. 441
CHAPTER 57: SEXUALLY TRANSMITTED INFECTIONS ................................................................................ 447
CHAPTER 58: ADULT AND PEDIATRIC EMERGENCY DRUGS...................................................................... 452
,CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE
MCCUISTION: PHARMACOLOGY: A PATIENT-CENTERED NURSING PROCESS
APPROACH, 11TH EDITION
MULTIPLE CHOICE
1. ALL OF THE FOLLOWING WOULD BE CONSIDERED SUBJECTIVE DATA, EXCEPT:
A. PATIENT-REPORTED HEALTH HISTORY
B. PATIENT-REPORTED SIGNS AND SYMPTOMS OF THEIR ILLNESS
C. FINANCIAL BARRIERS REPORTED BY THE PATIENT’S CAREGIVER
D. VITAL SIGNS OBTAINED FROM THE MEDICAL RECORD
ANS:D
SUBJECTIVE DATA IS BASED ON WHAT PATIENTS OR FAMILY MEMBERS COMMUNICATE TO THE NURSE.
PATIENT- REPORTED HEALTH HISTORY, SIGNS AND SYMPTOMS, AND CAREGIVER REPORTED FINANCIAL
BARRIERS WOULD BE CONSIDERED SUBJECTIVE DATA. VITAL SIGNS OBTAINED FROM THE MEDICAL
RECORD WOULD BE CONSIDERED OBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS:
PLANNING MSC: NCLEX: MANAGEMENT OF CLIENT CARE
2. THE NURSE IS USING DATA COLLECTED TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE
MOST DESIRABLE OUTCOMES. WHICH OF THE FOLLOWING STEPS IS THE NURSE APPLYING?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. GENERATE SOLUTIONS (PLANNING)
D. TAKE ACTION (NURSING INTERVENTIONS)
ANS:C
WHEN GENERATING SOLUTIONS (PLANNING), THE NURSE IDENTIFIES EXPECTED OUTCOMES AND USES
THE PATIENT’S PROBLEM(S) TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE MOST DESIRABLE
OUTCOMES. RECOGNIZING CUES (ASSESSMENT) INVOLVES THE GATHERING OF CUES (INFORMATION)
FROM THE PATIENT ABOUT THEIR HEALTH AND LIFESTYLE PRACTICES, WHICH ARE IMPORTANT FACTS
THAT AID THE NURSE IN MAKING CLINICAL CARE DECISIONS. PRIORITIZING HYPOTHESIS IS USED TO
ORGANIZE AND RANK THE PATIENT PROBLEM(S) IDENTIFIED. FINALLY, TAKING ACTION INVOLVES
IMPLEMENTATION OF NURSING INTERVENTIONS TO ACCOMPLISH THE EXPECTED OUTCOMES.
,DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: NURSING
INTERVENTION
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
3. A 5-YEAR-OLD CHILD WITH TYPE 1 DIABETES MELLITUS HAS HAD REPEATED HOSPITALIZATIONS
FOR EPISODES OF HYPERGLYCEMIA. THE PARENTS TELL THE NURSE THAT THEY CAN’T KEEP TRACK OF
EVERYTHING THAT HAS TO BE DONE TO CARE FOR THEIR CHILD. THE NURSE REVIEWS MEDICATIONS,
DIET, AND SYMPTOM MANAGEMENT WITH THE PARENTS AND DRAWS UP A DAILY CHECKLIST FOR THE
FAMILY TO USE. THESE ACTIVITIES ARE COMPLETED IN WHICH STEP OF THE NURSING PROCESS?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
D. TAKE ACTION (NURSING INTERVENTIONS)
ANS:D
TAKING ACTION THROUGH NURSING INTERVENTIONS IS WHERE THE NURSE PROVIDES PATIENT HEALTH
TEACHING, DRUG ADMINISTRATION, PATIENT CARE, AND OTHER INTERVENTIONS NECESSARY TO ASSIST
THE PATIENT IN ACCOMPLISHING EXPECTED OUTCOMES.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: NURSING
INTERVENTION
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
4. THE NURSE IS PREPARING TO ADMINISTER A MEDICATION AND REVIEWS THE PATIENT’S CHART
FOR DRUG ALLERGIES, SERUM CREATININE, AND BLOOD UREA NITROGEN (BUN) LEVELS. THE NURSE’S
ACTIONS ARE REFLECTIVE OF WHICH OF THE FOLLOWING?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. TAKE ACTION (NURSING INTERVENTIONS)
D. GENERATE SOLUTIONS (PLANNING)
ANS:A
RECOGNIZING CUES (ASSESSMENT) INVOLVES GATHERING SUBJECTIVE AND OBJECTIVE INFORMATION
ABOUT THE PATIENT AND THE MEDICATION. LABORATORY VALUES FROM THE PATIENT’S CHART
WOULD BE CONSIDERED COLLECTION OF OBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: ASSESSMENT MSC: NCLEX: MANAGEMENT OF CLIENT CARE
5. WHICH OF THE FOLLOWING WOULD BE CORRECTLY CATEGORIZED AS OBJECTIVE DATA?
A. A LIST OF HERBAL SUPPLEMENTS REGULARLY USED PROVIDED BY THE PATIENT.
,B. LAB VALUES ASSOCIATED WITH THE DRUGS THE PATIENT IS TAKING.
C. THE AGES AND RELATIONSHIP OF ALL HOUSEHOLD MEMBERS TO THE PATIENT.
D. USUAL DIETARY PATTERNS AND FOOD INTAKE.
ANS:B
OBJECTIVE DATA ARE MEASURED AND DETECTED BY ANOTHER PERSON AND WOULD INCLUDE LAB
VALUES. THE OTHER EXAMPLES ARE SUBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: ASSESSMENT MSC: NCLEX: MANAGEMENT OF CLIENT CARE
6. THE NURSE REVIEWS A PATIENT’S DATABASE AND LEARNS THAT THE PATIENT LIVES ALONE, IS
FORGETFUL, AND DOES NOT HAVE AN ESTABLISHED ROUTINE. THE PATIENT WILL BE SENT HOME WITH
THREE NEW MEDICATIONS TO BE TAKEN AT DIFFERENT TIMES OF THE DAY. THE NURSE DEVELOPS A
DAILY MEDICATION CHART AND ENLISTS A FAMILY MEMBER TO PUT THE PATIENT’S PILLS IN A PILL
ORGANIZER. THIS IS AN EXAMPLE OF WHICH ELEMENT OF THE NURSING PROCESS?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. TAKE ACTION (NURSING INTERVENTIONS)
D. GENERATE SOLUTIONS (PLANNING)
ANS:C
TAKING ACTION (NURSING INTERVENTIONS) INVOLVES EDUCATION AND PATIENT CARE IN ORDER TO
ASSIST THE PATIENT TO ACCOMPLISH THE GOALS OF TREATMENT.
DIF: COGNITIVE LEVEL: APPLYING (APPLICATION) TOP: NURSING PROCESS: NURSING INTERVENTION
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
7. A PATIENT WHO IS HOSPITALIZED FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
WANTS TO GO HOME. THE NURSE AND THE PATIENT DISCUSS THE PATIENT’S SITUATION AND DECIDE
THAT THE PATIENT MAY GO HOME WHEN ABLE TO PERFORM SELF-CARE WITHOUT DYSPNEA AND
HYPOXIA. THIS IS AN EXAMPLE OF WHICH PHASE OF THE NURSING PROCESS?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. TAKE ACTION (NURSING INTERVENTIONS)
D. GENERATE SOLUTIONS (PLANNING)
ANS:D
, GENERATING SOLUTIONS (PLANNING) INVOLVES DEFINING A SET OF INTERVENTIONS TO ACHIEVE THE
MOST DESIRABLE OUTCOMES, WHICH, FOR THIS PATIENT, MEANS BEING ABLE TO PERFORM SELF-CARE
ACTIVITIES WITHOUT DYSPNEA AND HYPOXIA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: PLANNING
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
8. A PATIENT WILL BE SENT HOME WITH A METERED-DOSE INHALER, AND THE NURSE IS
PROVIDING TEACHING. WHICH IS A CORRECTLY WRITTEN EXPECTED OUTCOME FOR THIS PROCESS?
A. THE NURSE WILL DEMONSTRATE THE CORRECT USE OF A METERED-DOSE INHALER TO THE
PATIENT.
B. THE NURSE WILL TEACH THE PATIENT HOW TO ADMINISTER MEDICATION WITH A METERED-
DOSE INHALER.
C. THE PATIENT WILL KNOW HOW TO SELF-ADMINISTER THE MEDICATION USING THE METERED-
DOSE INHALER.
D. THE PATIENT WILL INDEPENDENTLY ADMINISTER THE MEDICATION USING THE METERED-DOSE
INHALER AT THE END OF THE SESSION.
ANS:D
EXPECTED OUTCOMES MUST BE PATIENT-CENTERED AND CLEARLY STATE THE OUTCOME WITH A
REASONABLE DEADLINE AND SHOULD IDENTIFY COMPONENTS FOR EVALUATION.
DIF: COGNITIVE LEVEL: APPLYING (APPLICATION) TOP: NURSING PROCESS: PLANNING MSC:
NCLEX: MANAGEMENT OF CLIENT CARE
9. THE NURSE IS GENERATING SOLUTIONS (PLANNING) FOR A PATIENT WHO HAS CHRONIC LUNG
DISEASE AND HYPOXIA. THE PATIENT HAS BEEN ADMITTED FOR INCREASED OXYGEN NEEDS ABOVE A
BASELINE OF 2 L/MIN. THE NURSE GENERATES AN EXPECTED OUTCOMES STATING, “THE PATIENT WILL
HAVE OXYGEN SATURATIONS OF
>95% ON ROOM AIR AT THE TIME OF DISCHARGE FROM THE HOSPITAL.” WHAT IS WRONG WITH THIS
GOAL?
A. IT CANNOT BE EVALUATED.
B. IT IS NOT MEASURABLE.
C. IT IS NOT PATIENT-CENTERED.
D. IT IS NOT REALISTIC.
ANS:D
THE EXPECTED OUTCOME IS NOT REALISTIC BECAUSE THE PATIENT IS NOT USUALLY ON ROOM AIR AND
SHOULD NOT BE EXPECTED TO ATTAIN THAT EXPECTED OUTCOME BY DISCHARGE FROM THIS
HOSPITALIZATION.
PHARMACOLOGY A PATIENT-CENTERED NURSING
PROCESS APPROACH, 11TH EDITION
BY LINDA E. MCCUISTION | VERIFIED CHAPTER'S 1 - 58 |
COMPLETE ANSWERS
,TABLE OF CONTENTS
CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE ........................................................ 4
CHAPTER 02: DRUG DEVELOPMENT AND ETHICAL CONSIDERATIONS ...................................................... 11
CHAPTER 03: PHARMACOKINETICS AND PHARMACODYNAMICS .............................................................. 21
CHAPTER 04: PHARMACOGENETICS ........................................................................................................... 39
CHAPTER 05: COMPLEMENTARY AND ALTERNATIVE THERAPIES............................................................... 44
CHAPTER 06: PEDIATRIC CONSIDERATIONS................................................................................................ 50
CHAPTER 07: GERIATRIC CONSIDERATIONS ............................................................................................... 59
CHAPTER 08: DRUGS IN SUBSTANCE USE DISORDER.................................................................................. 66
CHAPTER 09: SAFETY AND QUALITY ........................................................................................................... 74
CHAPTER 10: DRUG ADMINISTRATION ....................................................................................................... 82
CHAPTER 11: DRUG CALCULATIONS ........................................................................................................... 88
CHAPTER 12: FLUID VOLUME AND ELECTROLYTES ..................................................................................... 94
CHAPTER 13: VITAMIN AND MINERAL REPLACEMENT ............................................................................. 106
CHAPTER 14: NUTRITIONAL SUPPORT ...................................................................................................... 115
CHAPTER 15: ADRENERGIC AGONISTS AND ANTAGONISTS ..................................................................... 125
CHAPTER 16: CHOLINERGIC AGONISTS AND ANTAGONISTS .................................................................... 132
CHAPTER 17: STIMULANTS ....................................................................................................................... 141
CHAPTER 18: DEPRESSANTS...................................................................................................................... 146
CHAPTER 19: ANTISEIZURE DRUGS ........................................................................................................... 155
CHAPTER 20: DRUGS FOR PARKINSONISM AND ALZHEIMER DISEASE ..................................................... 164
CHAPTER 21: DRUGS FOR NEUROMUSCULAR DISORDERS AND MUSCLE SPASMS .................................. 172
CHAPTER 22: ANTIPSYCHOTICS AND ANXIOLYTICS .................................................................................. 180
CHAPTER 23: ANTIDEPRESSANTS AND MOOD STABILIZERS ..................................................................... 189
CHAPTER 24: ANTIINFLAMMATORIES....................................................................................................... 198
CHAPTER 25: ANALGESICS ........................................................................................................................ 207
CHAPTER 26: PENICILLINS, OTHER BETA-LACTAMS, AND CEPHALOSPORINS .......................................... 216
CHAPTER 27: MACROLIDES, OXAZOLIDINONES, LINCOSAMIDES, GLYCOPEPTIDES, KETOLIDES, AND
LIPOPEPTIDES ............................................................................................................................................ 223
CHAPTER 28: TETRACYCLINES, GLYCYLCYCLINES, AMINOGLYCOSIDES, AND FLUOROQUINOLONES ...... 228
CHAPTER 29: SULFONAMIDES AND NITROIMIDAZOLES ANTIBIOTICS ..................................................... 233
,CHAPTER 30: ANTITUBERCULARS, ANTIFUNGALS, AND ANTIVIRALS ....................................................... 239
CHAPTER 31: ANTIMALARIALS, ANTHELMINTICS, AND PEPTIDES ............................................................ 250
CHAPTER 32: HIV- AND AIDS-RELATED DRUGS ......................................................................................... 254
CHAPTER 33: TRANSPLANT DRUGS ........................................................................................................... 259
CHAPTER 34: VACCINES ............................................................................................................................ 262
CHAPTER 35: ANTICANCER DRUGS ........................................................................................................... 268
CHAPTER 36: TARGETED THERAPIES TO TREAT CANCER .......................................................................... 274
CHAPTER 37: BIOLOGIC RESPONSE MODIFIERS ........................................................................................ 279
CHAPTER 38: UPPER RESPIRATORY DISORDERS ....................................................................................... 286
CHAPTER 39: LOWER RESPIRATORY DISORDERS ...................................................................................... 293
CHAPTER 40: CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS ................................... 301
CHAPTER 41: DIURETICS ........................................................................................................................... 314
CHAPTER 42: ANTIHYPERTENSIVES ........................................................................................................... 320
CHAPTER 43: ANTICOAGULANTS, ANTIPLATELETS, AND THROMBOLYTICS ............................................. 329
CHAPTER 44: ANTIHYPERLIPIDEMICS AND DRUGS TO IMPROVE PERIPHERAL BLOOD FLOW ................. 340
CHAPTER 45: GASTROINTESTINAL TRACT DISORDERS.............................................................................. 348
CHAPTER 46: ANTIULCER DRUGS .............................................................................................................. 358
CHAPTER 47: EYE AND EAR DISORDERS .................................................................................................... 367
CHAPTER 48: DERMATOLOGIC DISORDERS .............................................................................................. 373
CHAPTER 49: PITUITARY, THYROID, PARATHYROID, AND ADRENAL DISORDERS ..................................... 380
CHAPTER 50: ANTIDIABETICS .................................................................................................................... 392
CHAPTER 51: URINARY DISORDERS .......................................................................................................... 403
CHAPTER 52: PREGNANCY AND PRETERM LABOR .................................................................................... 410
CHAPTER 53: LABOR, DELIVERY, AND POSTPARTUM ............................................................................... 421
CHAPTER 54: NEONATAL AND NEWBORN ................................................................................................ 428
CHAPTER 55: WOMEN’S REPRODUCTIVE HEALTH .................................................................................... 431
CHAPTER 56: MEN’S HEALTH AND REPRODUCTIVE DISORDERS .............................................................. 441
CHAPTER 57: SEXUALLY TRANSMITTED INFECTIONS ................................................................................ 447
CHAPTER 58: ADULT AND PEDIATRIC EMERGENCY DRUGS...................................................................... 452
,CHAPTER 01: THE NURSING PROCESS AND PATIENT-CENTERED CARE
MCCUISTION: PHARMACOLOGY: A PATIENT-CENTERED NURSING PROCESS
APPROACH, 11TH EDITION
MULTIPLE CHOICE
1. ALL OF THE FOLLOWING WOULD BE CONSIDERED SUBJECTIVE DATA, EXCEPT:
A. PATIENT-REPORTED HEALTH HISTORY
B. PATIENT-REPORTED SIGNS AND SYMPTOMS OF THEIR ILLNESS
C. FINANCIAL BARRIERS REPORTED BY THE PATIENT’S CAREGIVER
D. VITAL SIGNS OBTAINED FROM THE MEDICAL RECORD
ANS:D
SUBJECTIVE DATA IS BASED ON WHAT PATIENTS OR FAMILY MEMBERS COMMUNICATE TO THE NURSE.
PATIENT- REPORTED HEALTH HISTORY, SIGNS AND SYMPTOMS, AND CAREGIVER REPORTED FINANCIAL
BARRIERS WOULD BE CONSIDERED SUBJECTIVE DATA. VITAL SIGNS OBTAINED FROM THE MEDICAL
RECORD WOULD BE CONSIDERED OBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS:
PLANNING MSC: NCLEX: MANAGEMENT OF CLIENT CARE
2. THE NURSE IS USING DATA COLLECTED TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE
MOST DESIRABLE OUTCOMES. WHICH OF THE FOLLOWING STEPS IS THE NURSE APPLYING?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. GENERATE SOLUTIONS (PLANNING)
D. TAKE ACTION (NURSING INTERVENTIONS)
ANS:C
WHEN GENERATING SOLUTIONS (PLANNING), THE NURSE IDENTIFIES EXPECTED OUTCOMES AND USES
THE PATIENT’S PROBLEM(S) TO DEFINE A SET OF INTERVENTIONS TO ACHIEVE THE MOST DESIRABLE
OUTCOMES. RECOGNIZING CUES (ASSESSMENT) INVOLVES THE GATHERING OF CUES (INFORMATION)
FROM THE PATIENT ABOUT THEIR HEALTH AND LIFESTYLE PRACTICES, WHICH ARE IMPORTANT FACTS
THAT AID THE NURSE IN MAKING CLINICAL CARE DECISIONS. PRIORITIZING HYPOTHESIS IS USED TO
ORGANIZE AND RANK THE PATIENT PROBLEM(S) IDENTIFIED. FINALLY, TAKING ACTION INVOLVES
IMPLEMENTATION OF NURSING INTERVENTIONS TO ACCOMPLISH THE EXPECTED OUTCOMES.
,DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: NURSING
INTERVENTION
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
3. A 5-YEAR-OLD CHILD WITH TYPE 1 DIABETES MELLITUS HAS HAD REPEATED HOSPITALIZATIONS
FOR EPISODES OF HYPERGLYCEMIA. THE PARENTS TELL THE NURSE THAT THEY CAN’T KEEP TRACK OF
EVERYTHING THAT HAS TO BE DONE TO CARE FOR THEIR CHILD. THE NURSE REVIEWS MEDICATIONS,
DIET, AND SYMPTOM MANAGEMENT WITH THE PARENTS AND DRAWS UP A DAILY CHECKLIST FOR THE
FAMILY TO USE. THESE ACTIVITIES ARE COMPLETED IN WHICH STEP OF THE NURSING PROCESS?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
D. TAKE ACTION (NURSING INTERVENTIONS)
ANS:D
TAKING ACTION THROUGH NURSING INTERVENTIONS IS WHERE THE NURSE PROVIDES PATIENT HEALTH
TEACHING, DRUG ADMINISTRATION, PATIENT CARE, AND OTHER INTERVENTIONS NECESSARY TO ASSIST
THE PATIENT IN ACCOMPLISHING EXPECTED OUTCOMES.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: NURSING
INTERVENTION
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
4. THE NURSE IS PREPARING TO ADMINISTER A MEDICATION AND REVIEWS THE PATIENT’S CHART
FOR DRUG ALLERGIES, SERUM CREATININE, AND BLOOD UREA NITROGEN (BUN) LEVELS. THE NURSE’S
ACTIONS ARE REFLECTIVE OF WHICH OF THE FOLLOWING?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. TAKE ACTION (NURSING INTERVENTIONS)
D. GENERATE SOLUTIONS (PLANNING)
ANS:A
RECOGNIZING CUES (ASSESSMENT) INVOLVES GATHERING SUBJECTIVE AND OBJECTIVE INFORMATION
ABOUT THE PATIENT AND THE MEDICATION. LABORATORY VALUES FROM THE PATIENT’S CHART
WOULD BE CONSIDERED COLLECTION OF OBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: ASSESSMENT MSC: NCLEX: MANAGEMENT OF CLIENT CARE
5. WHICH OF THE FOLLOWING WOULD BE CORRECTLY CATEGORIZED AS OBJECTIVE DATA?
A. A LIST OF HERBAL SUPPLEMENTS REGULARLY USED PROVIDED BY THE PATIENT.
,B. LAB VALUES ASSOCIATED WITH THE DRUGS THE PATIENT IS TAKING.
C. THE AGES AND RELATIONSHIP OF ALL HOUSEHOLD MEMBERS TO THE PATIENT.
D. USUAL DIETARY PATTERNS AND FOOD INTAKE.
ANS:B
OBJECTIVE DATA ARE MEASURED AND DETECTED BY ANOTHER PERSON AND WOULD INCLUDE LAB
VALUES. THE OTHER EXAMPLES ARE SUBJECTIVE DATA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION)
TOP: NURSING PROCESS: ASSESSMENT MSC: NCLEX: MANAGEMENT OF CLIENT CARE
6. THE NURSE REVIEWS A PATIENT’S DATABASE AND LEARNS THAT THE PATIENT LIVES ALONE, IS
FORGETFUL, AND DOES NOT HAVE AN ESTABLISHED ROUTINE. THE PATIENT WILL BE SENT HOME WITH
THREE NEW MEDICATIONS TO BE TAKEN AT DIFFERENT TIMES OF THE DAY. THE NURSE DEVELOPS A
DAILY MEDICATION CHART AND ENLISTS A FAMILY MEMBER TO PUT THE PATIENT’S PILLS IN A PILL
ORGANIZER. THIS IS AN EXAMPLE OF WHICH ELEMENT OF THE NURSING PROCESS?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. TAKE ACTION (NURSING INTERVENTIONS)
D. GENERATE SOLUTIONS (PLANNING)
ANS:C
TAKING ACTION (NURSING INTERVENTIONS) INVOLVES EDUCATION AND PATIENT CARE IN ORDER TO
ASSIST THE PATIENT TO ACCOMPLISH THE GOALS OF TREATMENT.
DIF: COGNITIVE LEVEL: APPLYING (APPLICATION) TOP: NURSING PROCESS: NURSING INTERVENTION
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
7. A PATIENT WHO IS HOSPITALIZED FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
WANTS TO GO HOME. THE NURSE AND THE PATIENT DISCUSS THE PATIENT’S SITUATION AND DECIDE
THAT THE PATIENT MAY GO HOME WHEN ABLE TO PERFORM SELF-CARE WITHOUT DYSPNEA AND
HYPOXIA. THIS IS AN EXAMPLE OF WHICH PHASE OF THE NURSING PROCESS?
A. RECOGNIZING CUES (ASSESSMENT)
B. ANALYZE CUES & PRIORITIZE HYPOTHESIS (ANALYSIS)
C. TAKE ACTION (NURSING INTERVENTIONS)
D. GENERATE SOLUTIONS (PLANNING)
ANS:D
, GENERATING SOLUTIONS (PLANNING) INVOLVES DEFINING A SET OF INTERVENTIONS TO ACHIEVE THE
MOST DESIRABLE OUTCOMES, WHICH, FOR THIS PATIENT, MEANS BEING ABLE TO PERFORM SELF-CARE
ACTIVITIES WITHOUT DYSPNEA AND HYPOXIA.
DIF: COGNITIVE LEVEL: UNDERSTANDING (COMPREHENSION) TOP: NURSING PROCESS: PLANNING
MSC: NCLEX: MANAGEMENT OF CLIENT CARE
8. A PATIENT WILL BE SENT HOME WITH A METERED-DOSE INHALER, AND THE NURSE IS
PROVIDING TEACHING. WHICH IS A CORRECTLY WRITTEN EXPECTED OUTCOME FOR THIS PROCESS?
A. THE NURSE WILL DEMONSTRATE THE CORRECT USE OF A METERED-DOSE INHALER TO THE
PATIENT.
B. THE NURSE WILL TEACH THE PATIENT HOW TO ADMINISTER MEDICATION WITH A METERED-
DOSE INHALER.
C. THE PATIENT WILL KNOW HOW TO SELF-ADMINISTER THE MEDICATION USING THE METERED-
DOSE INHALER.
D. THE PATIENT WILL INDEPENDENTLY ADMINISTER THE MEDICATION USING THE METERED-DOSE
INHALER AT THE END OF THE SESSION.
ANS:D
EXPECTED OUTCOMES MUST BE PATIENT-CENTERED AND CLEARLY STATE THE OUTCOME WITH A
REASONABLE DEADLINE AND SHOULD IDENTIFY COMPONENTS FOR EVALUATION.
DIF: COGNITIVE LEVEL: APPLYING (APPLICATION) TOP: NURSING PROCESS: PLANNING MSC:
NCLEX: MANAGEMENT OF CLIENT CARE
9. THE NURSE IS GENERATING SOLUTIONS (PLANNING) FOR A PATIENT WHO HAS CHRONIC LUNG
DISEASE AND HYPOXIA. THE PATIENT HAS BEEN ADMITTED FOR INCREASED OXYGEN NEEDS ABOVE A
BASELINE OF 2 L/MIN. THE NURSE GENERATES AN EXPECTED OUTCOMES STATING, “THE PATIENT WILL
HAVE OXYGEN SATURATIONS OF
>95% ON ROOM AIR AT THE TIME OF DISCHARGE FROM THE HOSPITAL.” WHAT IS WRONG WITH THIS
GOAL?
A. IT CANNOT BE EVALUATED.
B. IT IS NOT MEASURABLE.
C. IT IS NOT PATIENT-CENTERED.
D. IT IS NOT REALISTIC.
ANS:D
THE EXPECTED OUTCOME IS NOT REALISTIC BECAUSE THE PATIENT IS NOT USUALLY ON ROOM AIR AND
SHOULD NOT BE EXPECTED TO ATTAIN THAT EXPECTED OUTCOME BY DISCHARGE FROM THIS
HOSPITALIZATION.
